Skip to main content

United States News All stories

Every story in this section, newest first — page 330 of 373.

Grafa

Bank of America profit beats estimates as interest gains and dealmaking surge

Bank of America Corp. (NYSE:BAC) reported fourth-quarter net income of $7.65 billion, or 98 cents per share, as the nation’s second-largest lender successfully harnessed a rebound in investment banking and resilient consumer spending to overcome a high bar set by analysts.

Read more: Bank of America profit beats estimates as interest gains and dealmaking surge
Grafa
Health

AstraZeneca "supercharges" oncology pipeline with acquisition of Modella AI

AstraZeneca (NASDAQ:AZN) announced Tuesday at the J.P. Morgan Healthcare Conference that it has acquired Boston-based Modella AI, marking the first time a major pharmaceutical company has fully absorbed a specialized artificial intelligence firm.

Read more: AstraZeneca "supercharges" oncology pipeline with acquisition of Modella AI
Grafa
Health

ImmunityBio reports breakthrough survival in lung cancer with "Immunotherapy 2.0"

ImmunityBio (NASDAQ:IBRX) announced positive results Tuesday from its ANKTIVA® clinical program, signaling a potential paradigm shift in the treatment of advanced non-small cell lung cancer (NSCLC) for patients who have exhausted standard-of-care options.

Read more: ImmunityBio reports breakthrough survival in lung cancer with "Immunotherapy 2.0"
Grafa
Health

BriaCell reports sustained lung tumor clearance in early immunotherapy trial

BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced Tuesday that the first patient in its Bria-OTS trial achieved an 11-month sustained complete resolution of a lung metastasis, providing a significant early validation for the company’s personalized "off-the-shelf" immunotherapy platform.

Read more: BriaCell reports sustained lung tumor clearance in early immunotherapy trial
Grafa
Health

Fortress Biotech shares jump on FDA approval of ZYCUBO for Menkes disease

Fortress Biotech Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, secured a historic regulatory victory Tuesday as the U.S. Food and Drug Administration approved ZYCUBO® (copper histidinate) as the first-ever treatment for Menkes disease.

Read more: Fortress Biotech shares jump on FDA approval of ZYCUBO for Menkes disease